Imatinib

Acral/Lentiginous Melanoma

Dana-Farber Cancer InstituteSmall moleculePhase 2Dormant

B

57/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 42/ 100
Competitive Position: 95/ 100

Competitive context

19 Active assets in the Acral/Lentiginous Melanoma cohort.

Asset / Sponsor	Phase	Rating
Pembrolizumab Yonsei University	Phase 2	BB
Rivoceranib Peking University Cancer Hospital & Institute	Phase 3	B
Nilotinib Institute of Cancer Research, United Kingdom	Phase 2	B
Nivolumab Fred Hutchinson Cancer Center	Phase 2	B
Imatinib National Cancer Institute (NCI)	Phase 2	B

View all 29 →

Same molecule, other indications

Imatinib is also rated in:

chronic myeloid leukemiaDormant

BB

Indicative ·

71 / 100

blast phase chronic myelogenous leukemia, BCR-ABL1 positiveDormant

BB

Indicative ·

71 / 100

B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant

BB

Indicative ·

69 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.